Genomic Health, Inc.
) has announced positive study results that reaffirm the Oncotype
DX test's recent development as a significant predictor of prostate
cancer aggressiveness at the time of diagnosis - before
intervention with radiation or surgery.
A sub-analysis of a large Oncotype DX Genomic Prostate Score (GPS)
development study was presented at the American Urological
Association (AUA) Annual Meeting on May 20. This extensive
development study helps patients overcome tumor heterogeneity and
biopsy under-sampling and under-staging, which provides a precise
individualized risk assessment at the time of diagnosis. The study
demonstrated that GPS predicts time to clinical progression
regardless of post-surgery treatment.
The new analysis presented in the AUA meeting underscores the
robustness of the development study, which was specifically
developed and validated to identify those patients, who despite
being diagnosed with low rate prostate cancer, had more aggressive
disease and thus needed active surveillance. It also caters to the
critical treatment questions for such patients.
This explanatory analysis took into account a subset of 185
patients, divided into 3 subgroups, who experienced biochemical
recurrence after prostatectomy. Results from this analysis showed
that the Oncotype DX GPS can predict clinical recurrence for all
patients, irrespective of the type of post-surgery treatment they
have received. It was also found that for each therapy subgroup,
different biological pathways within the GPS are highly associated
with patient outcomes.
Based on the original development study, Genomic's GPS has already
been established as a significant test that helps men with very
low, low- or intermediate-risk of prostate cancer. This latest
analysis highlights the importance of including multiple biological
pathways to measure disease aggressiveness and the GPS test has
incorporated them successfully.
As a result of this sub-analysis, Genomic's Oncotype DX has emerged
as a truly personalized test that predicts disease aggressiveness
and addresses the challenges of biopsy under-sampling in cancer
Genomic Health is consistently expanding its focus on gaining
further understanding of prostate cancer biology, through the
exploration of future applications of Oncotype DX. Consequently, we
expect the company to garner an impressive share in the healthcare
market in the coming years.
Genomic Health currently has a Zacks Rank #3 (Hold). Some
better-ranked stocks worth considering in the biomedical industry
ANI Pharmaceuticals, Inc.
Myriad Genetics Inc.
). All these stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ANI PHARMACEUT (ANIP): Free Stock Analysis
GENOMIC HEALTH (GHDX): Free Stock Analysis
ILLUMINA INC (ILMN): Free Stock Analysis Report
MYRIAD GENETICS (MYGN): Free Stock Analysis
To read this article on Zacks.com click here.